Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via GlobeNewswire
Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous?
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its... 
Via Benzinga
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
Study will compare the profile of intramuscular versus intravenous SPL026 administration 
From Small Pharma Inc.
Via GlobeNewswire
Psyched: Canada's Psychedelic Therapy Guidelines, $39M Series B For Next-Gen Drugs, Mexico's Ancestral Roots & More
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries 
Via Benzinga
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Short-acting psychedelics biotech company Small Pharma Inc. 
Via Benzinga
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
From Small Pharma Inc.
Via GlobeNewswire
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors... 
Via Benzinga
How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study
The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity... 
Via Benzinga
First Patient Dosed in Small Pharma’s Drug Interaction Study
Open-label study will assess the interaction between SSRI antidepressants and SPL026 
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma To Support University College London Research Project on Neuroplasticity
Small Pharma will provide SPL026 for the brain-imaging study, which seeks to explore how psychedelic-induced brain changes impact cognition, behaviour and well-being 
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
From Small Pharma Inc.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 24, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
Via Benzinga
Small Pharma to Participate in November Investor and Healthcare Conferences
From Small Pharma Inc.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From November 8, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 3, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 
Via Benzinga
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out
Small Pharma Inc. 
Via Benzinga
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
From Small Pharma Inc.
Via GlobeNewswire
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 
Via Benzinga
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 
Via Benzinga
This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More
Short-acting psychedelics biotech firm Small Pharma Inc. 
Via Benzinga
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
From Small Pharma Inc.
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 
Via Benzinga
Small Pharma's Q2 2023 Financial Results, 'Ultra Short-Acting Psychedelic Program' Underway
Small Pharma Inc. (OTCQB: DMTTF), a biotech company developing short-acting psychedelic-assisted therapies for diverse mental health disorders, reported its financial results for the three and six... 
Via Benzinga
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback